ARIEL4 Clinical Trial
An Investigational Drug for Advanced Ovarian Cancer
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL) is a Phase 3 trial for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens.
Participating in the ARIEL4 Clinical Trial
The purpose of the ARIEL4 study is to compare the effects of the investigational drug rucaparib versus chemotherapy standard of care in approximately 345 women with high-grade ovarian, fallopian tube, or primary peritoneal cancer who have had at least two prior chemotherapy regimens. The effects of rucaparib versus standard of care will be evaluated in defined groups of patients. Two thirds of the participants enrolled in this study will receive rucaparib. The other third of participants will receive standard of care therapy. If you qualify for the ARIEL4 trial, you will receive the following as part of the study: standard-of-care and study related clinical exams, blood tests, imaging scans of your cancer, lab test results including BRCA and the other biomarker tests, the study medication (rucaparib or chemotherapy) and other assessments. Patients who were treated with chemotherapy on the main study and then experience a worsening of their ovarian cancer may be eligible to receive rucaparib after they discontinue chemotherapy; your study doctor will discuss other treatment options with you.